ConjuChem
| Public (TSX has Delisted this Stock) | |
| Industry | Biotechnology |
| Headquarters | Montreal, Quebec, Canada |
Key people | Mark Perrin |
| Products | Drug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC) |
Number of employees | 44 |
| Website | www.conjuchem.com |
ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Canada[1] which is credited with inventing the experimental peptide hormone CJC-1295.[2][3]
It employs 45 people, 90% of whom are in research and development.
References
- ↑ "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
- ↑ Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X.
- ↑ "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Retrieved 18 June 2015.
External links
This article is issued from Wikipedia - version of the Friday, June 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.